Vaccine Formulation/Presentation Guide

For further details please scroll down and click to see the Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) Emergency Use Authorization Fact Sheets or contact US Medical Information at PfizerMedicalInformation.com or 1-800-438-1985.

Emergency Use Authorization

Emergency uses of the vaccines have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and 12 years and older for the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com.

Interchangeability (Primary Series for Individuals 12 Years of Age and Older)

When prepared according to their respective instructions for use, the FDA-approved COMIRNATY® and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older can be used interchangeably without presenting any safety or effectiveness concerns.

Because of the potential for vaccine administration errors, including dosing errors, vaccine presentations should only be used for the ages specified on the vial labels, cartons, or the respective age-based Fact Sheet. The information in the Fact Sheets supersedes the information printed on the vial labels and cartons.
Low dead-volume syringes and/or needles can be used to extract 6 doses from a single multiple dose vial. If standard syringes and needles are used, there may not be sufficient volume to extract 6 doses from a single vial.

**Certain kinds of immunocompromise** refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

Please see full Important Safety Information and Indication & Authorized Use on pages 5 through 7.

Before administration, please [scroll down](#) and [click](#) or visit [cvd vaccine-us.com](http://cvd vaccine-us.com) to review the full Prescribing Information (COMIRNATY Purple Cap or Gray Cap) and respective Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent EUA Fact Sheets.
### Verify the vials (including labels) prior to preparation and administration to help avoid dosing errors

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Vial Cap Color</th>
<th>Dose</th>
<th>Dose Volume</th>
<th>Amount of Diluent Needed per Vial</th>
<th>Doses per Vial</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 years and older</td>
<td>Gray</td>
<td>30 mcg</td>
<td>0.3 mL</td>
<td>NO DILUTION</td>
<td>Multiple dose vial: 6 doses per vial</td>
</tr>
<tr>
<td>12 years and older*</td>
<td>Gray</td>
<td>30 mcg</td>
<td>0.3 mL</td>
<td>NO DILUTION</td>
<td>6 doses per vial</td>
</tr>
<tr>
<td>12 years and older*</td>
<td>Purple</td>
<td>30 mcg</td>
<td>0.3 mL</td>
<td>1.8 mL</td>
<td>6 doses per vial (after dilution)</td>
</tr>
</tbody>
</table>

#### Storage Conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Storage Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ultra-Low-Temperature (ULT) Freezer</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>[-90 °C to -60 °C (-130 °F to -76 °F)]</td>
<td>12 months[^1]</td>
</tr>
<tr>
<td><strong>Freezer</strong></td>
<td>DO NOT STORE</td>
</tr>
<tr>
<td>[-25 °C to -15 °C (-13 °F to 5 °F)]</td>
<td>2 Weeks</td>
</tr>
<tr>
<td><strong>Refrigerator</strong></td>
<td></td>
</tr>
<tr>
<td>[2 °C to 8 °C (35 °F to 46 °F)]</td>
<td>10 Weeks</td>
</tr>
<tr>
<td><strong>Room Temperature</strong></td>
<td></td>
</tr>
<tr>
<td>[8 °C to 25 °C (46 °F to 77 °F)]</td>
<td>2 hours prior to dilution (including any thaw time)</td>
</tr>
<tr>
<td>After First Puncture</td>
<td></td>
</tr>
<tr>
<td>[2 °C to 25 °C (35 °F to 77 °F)]</td>
<td>Discard after 12 hours</td>
</tr>
</tbody>
</table>

### Low dead-volume syringes and/or needles can be used to extract 6 doses from a single multiple dose vial. If standard syringes and needles are used, there may not be sufficient volume to extract 6 doses from a single vial.

[^1]: For vaccination of individuals advancing into the next age group (11 years of age turning 12 years of age) between any primary series dose, refer to the respective age-based Fact Sheet for Healthcare Providers for instructions for administration.

[^2]: ONLY use sterile 0.9% Sodium Chloride Injection, USP as the diluent. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.

[^3]: Regardless of storage condition, gray cap vaccine should not be used after 12 months from the date of manufacture printed on the vial and carton.

[^4]: Regardless of storage condition, purple cap vaccine should not be used past the 12-month expiry. For vials with expiry dates of October 2021 through March 2022, the printed date on the label/carton reflects 6-month expiry. For vials with expiry dates of June 2022 or beyond, the printed date on the label/carton reflects 9-month expiry.

Please see following page for dosage and storage information for individuals 6 months through 4 years of age and 5 through 11 years of age.

Please see full Important Safety Information and Indication & Authorized Use on pages 5 through 7.

Before administration, please scroll down and click or visit cvdvaccine-us.com to review the full Prescribing Information (COMIRNATY Purple Cap or Gray Cap) and respective Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent EUA Fact Sheets.
### Vaccine Formulation/Presentation Guide

For eligible individuals **6 months through 4 years of age and 5 through 11 years of age**

For vaccination of individuals advancing into the next age group (4 years of age turning 5 years of age or 11 years of age turning 12 years of age) between any primary series dose, refer to the respective age-based Fact Sheet for Healthcare Providers for instructions for administration.

<table>
<thead>
<tr>
<th>Age Group</th>
<th><strong>6 months through 4 years</strong> (See additional information in boxed maroon text to the right of table)</th>
<th><strong>5 through 11 years</strong> (&quot;Age 5y to &lt;12y&quot; on vial label)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vial Cap Color</td>
<td>Maroon</td>
<td>Orange</td>
</tr>
<tr>
<td>Dose</td>
<td>3 mcg</td>
<td>10 mcg</td>
</tr>
<tr>
<td>Dose Volume</td>
<td>0.2 mL</td>
<td>0.2 mL</td>
</tr>
<tr>
<td>Amount of Diluent Needed per Vial*</td>
<td>2.2 mL</td>
<td>1.3 mL</td>
</tr>
<tr>
<td>Doses per Vial</td>
<td>10 doses per vial (after dilution)</td>
<td>10 doses per vial (after dilution)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Storage Conditions</th>
<th><strong>Ultra-Low-Temperature (ULT) Freezer [-90 °C to -60 °C (-130 °F to -76 °F)]</strong></th>
<th><strong>DO NOT STORE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Freezer [-25 °C to -15 °C (-13 °F to 5 °F)]</td>
<td>10 weeks</td>
<td>10 weeks</td>
</tr>
<tr>
<td>Refrigerator [2 °C to 8 °C (35 °F to 46 °F)]</td>
<td>12 hours prior to dilution (including any thaw time)</td>
<td>12 hours prior to dilution (including any thaw time)</td>
</tr>
<tr>
<td>Room Temperature [8 °C to 25 °C (46 °F to 77 °F)]</td>
<td>12 hours prior to dilution (including any thaw time)</td>
<td>12 hours prior to dilution (including any thaw time)</td>
</tr>
<tr>
<td>After First Puncture [2 °C to 25 °C (35 °F to 77 °F)]</td>
<td>Discard after 12 hours</td>
<td>Discard after 12 hours</td>
</tr>
</tbody>
</table>

Compatible low dead-volume syringe and/or needle pairings may successfully withdraw 10 (Orange Cap and Maroon Cap Vials) doses of the vaccine dependent on presentation vial, but not all syringe combinations have been assessed or have a low dead-volume that is small enough to allow extraction of all doses.

*ONLY use sterile 0.9% Sodium Chloride Injection, USP as the diluent. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.

†Regardless of storage condition, maroon and orange cap vaccines should not be used after 12 months from the date of manufacture printed on the vial and cartons.

‡Vials should be discarded 12 hours after dilution, even though some vial and carton labels may state that a vial should be discarded 6 hours after dilution. The information in the Fact Sheet supersedes the information printed on vial labels and cartons.

The vial labels may state “Age 2y to < 5y” or “Age 6m to < 5y” and carton labels may state “For age 2 years to < 5 years” or “For age 6 months to < 5 years.” Vials with either printed age range can be used for individuals 6 months through 4 years of age.

---

Please see full Important Safety Information and Indication & Authorized Use on pages 5 through 7. Before administration, please scroll down and click or visit cvdvaccine-us.com to review the full Prescribing Information (COMIRNATY Purple Cap or Gray Cap) and respective Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent EUA Fact Sheets.
Important Safety Information
Do not administer Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, or Pfizer-BioNTech COVID-19 Vaccine, Bivalent to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of these vaccines.

Management of Acute Allergic Reactions
Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

Myocarditis and Pericarditis
Myocarditis and pericarditis have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Postmarketing safety data with Pfizer-BioNTech COVID-19 Vaccine are relevant to Pfizer-BioNTech COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.

Postmarketing data with authorized or approved monovalent mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following receipt of the second primary series dose or first booster dose, with most booster doses likely administered at least 5 months after completing primary vaccination. For the Pfizer-BioNTech COVID-19 Vaccine, the observed risk is higher among adolescent males and adult males under 40 years of age than among females and older males, and the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).

Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting.

Continued on next page.

Important Safety Information and Indication & Authorized Use

Altered Immunocompetence
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Limitation of Effectiveness
Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent may not protect all vaccine recipients.

Adverse Reactions

Primary Series Adverse Events:
Pfizer-BioNTech COVID-19 Vaccine
In a clinical study (3 mcg modRNA) in participants 6 through 23 months of age, adverse reactions following administration of any dose included irritability (68.4%), decreased appetite (38.6%), tenderness at the injection site (26.4%), injection site redness (17.8%), fever (14.4%), injection site swelling (7.3%), and lymphadenopathy (0.2%).

In a clinical study (3 mcg modRNA) in participants 2 through 4 years of age, adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (94.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY
In clinical studies (30 mcg modRNA) of adolescents 12 through 15 years of age, the most commonly reported adverse reactions (≥8%) were pain at the injection site (88.6%), fatigue (70.1%), headache (64.9%), muscle pain (45.5%), chills (41.5%), joint pain (27.5%), fever (17.8%), and injection site swelling (10.6%).

In clinical studies (30 mcg modRNA) of participants 16 through 55 years of age, the most commonly reported adverse reactions (≥10%) were pain at the injection site (88.6%), fatigue (70.1%), headache (64.9%), muscle pain (45.5%), chills (41.5%), joint pain (27.5%), fever (17.8%), and injection site swelling (10.6%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, the most commonly reported adverse reactions (≥8%) were pain at the injection site (94.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

In a clinical study (3 mcg modRNA) in participants 2 through 4 years of age, adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (94.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

In a clinical study (3 mcg modRNA) in participants 2 through 4 years of age, adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (94.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

In a clinical study (3 mcg modRNA) in participants 2 through 4 years of age, adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (94.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

In a clinical study (3 mcg modRNA) in participants 2 through 4 years of age, adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (94.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

In a clinical study (3 mcg modRNA) in participants 2 through 4 years of age, adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (94.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

In a clinical study (3 mcg modRNA) in participants 2 through 4 years of age, adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (94.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).
In clinical studies (30 mcg modRNA) of participants 56 years of age and older, the most commonly reported adverse reactions (≥10%) were pain at the injection site (78.2%), fatigue (56.9%), headache (45.9%), muscle pain (32.5%), chills (24.8%), joint pain (21.5%), injection site swelling (11.8%), fever (11.5%), and injection site redness (10.4%).

**Booster Dose Adverse Events:**

**Pfizer-BioNTech COVID-19 Vaccine**

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of a single booster dose were injection site pain (73.9%), fatigue (45.6%), headache (34.0%), muscle pain (18.3%), injection site swelling (16.4%), injection site redness (15.6%), chills (10.5%), fever (6.7%), joint pain (6.7%), diarrhea (4.9%), lymphadenopathy (2.5%), and vomiting (2.4%).

**Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY**

In a clinical study (30 mcg modRNA) of participants 18 through 55 years of age, adverse reactions following administration of a first booster dose were pain at the injection site (83.0%), fatigue (63.7%), headache (48.4%), muscle pain (39.1%), chills (29.1%), joint pain (25.3%), lymphadenopathy (5.2%), nausea (0.7%), decreased appetite (0.3%), rash (0.3%), and pain in extremity (0.3%).

**Post Authorization Experience**

Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (e.g., rash, pruritus, urticaria, angioedema), diarrhea, vomiting, pain in extremity (arm), and syncope have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Myocarditis and pericarditis have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of Pfizer-BioNTech COVID-19 Vaccine and post authorization use of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

**COMIRNATY**

**Indication & Authorized Use**

COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. It is also authorized for emergency use to provide a third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise.

**Pfizer-BioNTech COVID-19 Vaccine**

**Authorized Use**

Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.

Continued on next page.
Interchangeability (Primary Series for Individuals 12 Years of Age and Older)

When prepared according to their respective instructions for use, the FDA-approved COMIRNATY and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older can be used interchangeably without presenting any safety or effectiveness concerns.

Because of the potential for vaccine administration errors, including dosing errors, vaccine presentations should only be used for the ages specified on the vial labels, cartons, or the respective age-based Fact Sheet. The information in the Fact Sheets supersedes the information printed on the vial labels and cartons.

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

Authorized Use


References:

Please see full Important Safety Information and Indication & Authorized Use on pages 5 and 6.

Before administration of Pfizer-BioNTech COVID-19 Vaccine, please click to see

Fact Sheets for individuals 6 months through 4 years of age

EUA Fact Sheet for Vaccination Providers (6 months through 4 years of age), DILUTE BEFORE USE, Maroon Cap
Recipients and Caregivers Fact Sheet (6 months through 4 years of age)

Fact Sheets for individuals 5 through 11 years of age

EUA Fact Sheet for Vaccination Providers (5 through 11 years of age), DILUTE BEFORE USE, Orange Cap
Recipients and Caregivers Fact Sheet (5 through 11 years of age)

Before administration of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), please click to see

EUA Fact Sheet for Vaccination Providers, Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Booster Dose 12 years of age and older), DO NOT DILUTE, Gray Cap
Recipients and Caregivers Fact Sheet: (Primary Series and Bivalent Booster Dose 12 years of age and older)

Before administration of Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY (COVID-19 Vaccine, mRNA), please click to see

Full Prescribing Information (Primary Series 12 years of age and older), DO NOT DILUTE, Gray Cap
Full Prescribing Information (Primary Series 12 years of age and older), DILUTE BEFORE USE, Purple Cap
EUA Fact Sheet for Vaccination Providers (Primary Series 12 years of age and older), DO NOT DILUTE, Gray Cap
EUA Fact Sheet for Vaccination Providers (Primary Series 12 years of age and older), DILUTE BEFORE USE, Purple Cap
Recipients and Caregivers Fact Sheet: (Primary Series and Bivalent Booster Dose 12 years of age and older)

Find additional resources about the vaccine at www.cvdvaccine-us.com